about
Cancer genetic risk assessment for individuals at risk of familial breast cancerEvidence that BRCA1- or BRCA2-associated cancers are not inevitableCommon breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersOpportunities and Challenges of Genotyping Patients With Nephrotic Syndrome in the Genomic EraTwo-phase and family-based designs for next-generation sequencing studiesGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskSolid tumor second primary neoplasms: who is at risk, what can we do?Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation CarriersFunctional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi originVariation in breast cancer risk in BRCA1 and BRCA2 mutation carriersContralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modelingRisk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancerReproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE studyPopulation-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.A frailty-model-based approach to estimating the age-dependent penetrance function of candidate genes using population-based case-control study designs: an application to data on the BRCA1 gene.Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer.The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes.Common genetic variants and modification of penetrance of BRCA2-associated breast cancerBRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.Incorporating prior biologic information for high-dimensional rare variant association studiesMap making in the 21st century: charting breast cancer susceptibility pathways in rodent models.Breast cancer after chest radiation therapy for childhood cancer.Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study populationCommon variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriersSNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population.Multicenter breast cancer collaborative registry.Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell linesLocal therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriersBreast-cancer risk in families with mutations in PALB2
P2860
Q24203650-501286EB-F3EC-4080-A307-DAE488EDD61EQ24600238-D953FF0C-31B0-4B1C-9498-5E256A82C3D7Q24655824-841B8748-C9D3-46C1-8BDE-CE19619301A1Q26799197-BA87167A-D2E4-4DA8-89CC-756A340FD457Q26828744-ADA8149B-4016-4175-9942-6610D68C8679Q27008356-DF135470-A002-4179-A20A-93FFCA9BF90DQ27026266-5F07E4DB-76C2-45B8-888F-DAC8CC9B21A1Q28085448-732FFD25-5DFE-4A54-97DB-A6C068D6839EQ28260374-CAC31A20-6313-42C3-A968-AB487898436EQ28386156-2CF4FD26-6161-43AA-A6D7-C8A1D4CA5625Q30410984-8FF99571-B604-484F-A789-C5AD941384B3Q30415050-00D73167-3207-4A6D-96D7-6CE2AA75E41EQ30426205-BDBCB368-C129-4F22-A2D1-13E6062C79B1Q30426599-CCEF0AF5-1A34-49C3-A74B-1B3590612819Q30430808-D0BF0C78-33F6-44CB-B9C3-E9B21D967075Q30432062-9B288C26-FFCC-4EF9-AF67-F91EE1A919EFQ30432372-3FAE3C31-A8F6-4436-882E-08B53F724AB8Q30432746-97BB0F2F-6D88-47F5-88F3-18A8BAD606B3Q30433040-8257896F-0542-45F8-9420-DDAAC2FE079EQ30433319-A665C1DF-7450-43B8-BDF9-8EEFD0ED1826Q30438623-713C16B3-88E1-455C-987F-BA74499E6916Q30494804-CB28873C-D356-455A-B979-178863686F1AQ33408340-1F05288C-4780-48AD-BF44-4D8A6D755419Q33549627-6DAFB64C-0BE8-4BE7-9213-C9E863075FDEQ33675997-AB4FBCAD-749E-43AC-AE2F-D28C67BA216CQ33687533-AFDC4D54-D0A0-4CE6-87E0-08FECB4F18E3Q33734037-6BFE77FA-9D81-4FE5-9212-7F15D56F5A23Q33742096-925C145A-2980-4E32-98C1-EADFDB2071B9Q33750060-5C01BB4D-C339-42CE-8E91-DD493ECB8541Q33758994-476BF0F1-8CFC-4C41-B7A0-D90D837A107CQ33908246-7BCDB9AA-798E-464C-8927-7A9AD99B0BE5Q33910979-677E1B3B-12E5-49E8-BF37-41E98DFA7765Q33919320-A8473077-0448-45D3-B2F0-0BBE060096A9Q33947829-278FD7F8-0EF0-4265-BC91-E9BD8A8DDC13Q33959543-0A648B97-1E22-42BF-87D9-49D11169B90CQ34019748-0DB624B8-7196-4D9F-B7C8-123631F65B1AQ34060031-A2964A98-6679-436F-98E5-FDF36469B977Q34114943-21D36A78-03C7-4300-89B3-639DE0CB2FF4Q34115636-BD6C48A2-8AFC-46DD-A8DF-3B5FC34FE656Q34148873-D6E479D6-9597-4EBE-909D-1ED28538B6C7
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Variation of breast cancer risk among BRCA1/2 carriers
@nl
Variation of breast cancer risk among BRCA1/2 carriers.
@ast
Variation of breast cancer risk among BRCA1/2 carriers.
@en
type
label
Variation of breast cancer risk among BRCA1/2 carriers
@nl
Variation of breast cancer risk among BRCA1/2 carriers.
@ast
Variation of breast cancer risk among BRCA1/2 carriers.
@en
prefLabel
Variation of breast cancer risk among BRCA1/2 carriers
@nl
Variation of breast cancer risk among BRCA1/2 carriers.
@ast
Variation of breast cancer risk among BRCA1/2 carriers.
@en
P2093
P2860
P50
P3181
P356
P1476
Variation of breast cancer risk among BRCA1/2 carriers.
@en
P2093
Amanda J Hummer
Bryan Langholz
Charles F Lynch
Colin B Begg
Duncan C Thomas
Jonine L Bernstein
Kathleen E Malone
Robert W Haile
P2860
P304
P3181
P356
10.1001/JAMA.2007.55-A
P407
P577
2008-01-01T00:00:00Z